Navigation Links
TB Patients in Marginalised Groups Need Social Support for Effective Medical Treatment

The latest Journal of Advanced Nursing reports that many socially disadvantaged UK residents suffering from Tuberculosis (TB), need social help for better treatment .

A research across London by TB specialists found that the growing numbers pose a challenge for agencies trying to halt the spread of the disease.

"TB has risen considerably in major European cities in the last 10 years and London is no exception" says lead researcher Dr Gill Craig from The City Universitys Institute of Health Sciences.

"Increased migration, poverty, HIV, poor quality and overcrowded housing, homelessness, the failure of TB control in institutionalised populations and lifestyle factors related to drug misuse have all played a role.

"Models of care that can cater for both the social and medical needs of patients are an essential, but often neglected, aspect of TB management and one that needs to be urgently addressed if we are to tackle this growing health issue."

The study, which covered 250 patients attending one London hospital between January 2003 and January 2005, found that the disease was more common among men (57 per cent) and people aged between 20 and 39 (60 per cent).

Other key findings included:

* 42 per cent of TB patients were from Africa, 27 per cent from Asia, 24 per cent from the UK and 6 per cent from the rest of Europe.

* Just under a third were homeless, with 11 per cent living in a hostel or on the streets and a further 21 per cent staying with friends or relatives. 39 per cent were receiving welfare benefits and 13 per cent had no income.

* 16 per cent werent registered with a family doctor, 13 per cent were seeking asylum and 16 per cent did not speak English as their first language.

* More than a third anticipated problems taking their medicine and 30 per cent had no-one to remind them, suggesting a lack of social support. '"/>




Page: 1 2

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patients often assume wrongly that they are allergic to penicillin
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. Hemochromatosis Patients Blood is Safe
9. Patients Pressure Would Result In Overprescription
10. Risk Of Decongestants In Hypertensive Patients
11. Interference helps Heart Patients
Post Your Comments:
(Date:9/5/2008)...odels are enhanced by taking into account risk fac... according to research teams led by epidemiologist... Center in two complementary papers appearing in t.... , In the first study to focus on African-Ameri...creased exposure to certain risks. Based upon thes...
(Date:9/4/2008)...e Medicare Advantage (MA) plans will be paid an av...red to what the same enrollee would have cost in t...ccording to a new report from The Commonwealth Fun...dated by the Medicare Improvements for Patients an... effect beginning in 2010 had been fully in place...
(Date:9/4/2008)...pancreatic tumors , , THURSDAY, Sept. 4 ...coveries involving genetic mutations of two deadly...reatic cancer -- may lead to new treatments and ev...present the most complete genetic analysis to date...map of these deadly cancers," Kenneth Kinzler, a p...
(Date:9/4/2008)...RNewswire/ -- Martin Schiff, M.D.,is an illustriou...weight,control and weight loss. His career is deta...he West," "Who,s Who in America," "Who,s Who in,th...and other honor rolls., Dr. Schiff recently retir...ate, misleading theories and notions concerning we...
Breaking Medicine News(10 mins):Health News:Creating lung cancer risk models for specific populations refines prediction 2Health News:Creating lung cancer risk models for specific populations refines prediction 3Health News:Extra payments to Medicare Advantage plans to total $8.5 billion in 2008 2Health News:Genetic Mutations Linked to Deadly Cancers 2Health News:Genetic Mutations Linked to Deadly Cancers 3Health News:Genetic Mutations Linked to Deadly Cancers 4Health News:Phone World-famed Martin Schiff, M.D., at 310-454-6172 for Free Weight Loss 'No Diet, No Stuff' Method. Hates Diets, Loves to Have People Help Themselves 2
...alyzing the neuronal receptor activity in the post...ia, researchers at the University of Pennsylvania ...ists at the City University of New York, have foun...h level of erbB4 receptor activity and reduced NMD...
...a of subjecting drug addicts to shock therapy as a... debates and controversies. Now, the Scottish Exec...rapy //. Shock therapy technically labeled as Neu...with the use of self-adhesive electrodes inserted ...
...bane childcare center, a tuberculosis case alerts ...diagnosed in a childcare worker, who works at the ...Mount Ommaney in west Brisbane. Dr Michael Whitby... Medical Association (AMA) said that children’s (m...
...ast Victoria Sale Hospital's two pediatricians, Jo...ions with three months notice with three months no...xpected for at least six months. This has led to .... Sale obstetrician Dr Refaat Guirguis has said th...
Other Medicine News:Health News:Schizophrenia Complicates With Altered Receptor Activity 2Health News:Schizophrenia Complicates With Altered Receptor Activity 3
(Date:9/3/2008)... that Multaq(R) (dronedarone) decreased the risk o...n or atrial flutter already adequatel... N.J., Sept. 3 /- The resul...ENA study were presented today at,the clinical tri...ology,congress 2008, in Munich, Germany. Previous ...
(Date:9/3/2008)...erations, Updates Zingo Launch Progress and Adlea ... Conference Call Today at 11:30 am ET,...-FirstCall/ -- Anesiva,Inc. (Nasdaq: ANSV ) anno...ations to focus on commercial and late-stage produ...pecialty pharmaceutical pain management,company. T...
(Date:9/3/2008)...uated in Repeat-Dosing Study in Subjects with ALS,... -- Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) ann... trial (SB-509-801) to evaluate its drug, SB-509, ...motor-neuron disease for which there,are limited t...-509, is an injectable formulation of a plasmid,en...
(Date:9/2/2008).../- Forest Laboratories, Inc...day announced results from,two global Phase III st...nhaled anticholinergic for the treatment of patien...D). In both the ACCLAIM/COPD I&II,(AClidinium CLin...te to,Severe COPD Patients) studies, once-daily ac...
Breaking Medicine Technology:Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 2Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 3Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 4Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation 5Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 2Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 3Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 4Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 2Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 3Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 4Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 5Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD) 6Gerber Scientific to Present at 10th Annual Needham Growth Stock Conference 9000 1Gerber Scientific to Present at 10th Annual Needham Growth Stock Conference 9000 2Transcript of Elizabeth Mazzocchi Press Conference 8996 1Transcript of Elizabeth Mazzocchi Press Conference 8996 2Transcript of Elizabeth Mazzocchi Press Conference 8996 3Transcript of Elizabeth Mazzocchi Press Conference 8996 4Transcript of Elizabeth Mazzocchi Press Conference 8996 5Exelixis Announces January 10 Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference 2415 1Oncolytics Biotech Inc Announces Filing of Phase 1 2 Clinical Trial with REOLYSIN 28R 29 2411 1Oncolytics Biotech Inc Announces Filing of Phase 1 2 Clinical Trial with REOLYSIN 28R 29 2411 2
...Donnelly, MT (ASCP) Contributing Editor , ,Qu...y to meeting the needs of doctors and patients by ...hods. Vendors of these systems can be a valuable r...tocols to help lab managers ensure that analytical...oping suitable QC materials for today,s laboratori...
...l S. Singer, M.D., Ph.D. Contributing Editor Harva...l for heart failure in African American patients h...espond differently to the same medication. This c...edications, and in many cases is due to individual...ics focuses on these issues, valuable new laborato...
Other Medicine Technology:New Quality Control Systems for Every Laboratory Application 2New Quality Control Systems for Every Laboratory Application 3Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy. 2Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy. 3
... Integrity family of pacemakers features several o... today's worldwide pacing market. Offering an unpa...gnostic information, the system builds on the popu...,It incorporates the exclusive ventricular AutoC...
IntelliVue Information Center combines the real-time monitoring surveillance of a central station with sophisticated clinical analysis tools. Moreover, the Information Center is equipped with Philips
...troSpec™, is an imaging agent that provides ...ging for patients five years of age or older with ...llows physicians to see clearly the "function" of ...ing in a reliable diagnosis. NeutroSpec attaches t...
...iTime® is an enterprise-wide staff scheduling ... scheduling process through the synchronization an...automatically generates and maintains staff schedu...nd overtime; manages shift and work location sched...
Medicine Products: